We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Bone marrow involvement in systemic lupus erythematosus.
- Authors
Chalayer, E.; Costedoat-Chalumeau, N.; Beyne-Rauzy, O.; Ninet, J.; Durupt, S.; Tebib, J.; Asli, B.; Lambotte, O.; Ffrench, M.; Vasselon, C.; Cathébras, P.
- Abstract
Background: Besides peripheral cytopenias, bone marrow abnormalities, such as fibrosis, pure red cell aplasia and aplastic anemia have been reported in patients with systemic lupus erythematosus (SLE), suggesting that bone marrow may be a 25 target organ in SLE. Aim: Our objective was to describe this bone marrow involvement. Methods: This registry is a nationwide retrospective study. Centers provided data concerning medical history, SLE manifestations, type of hematologic disorder, treatments and outcome. Bone marrow aspirations and/or biopsies were transferred for centralized review. Results: Thirty patients from 19 centers were included. Central hematologic manifestations comprised bone marrow fibrosis (n=17; 57%), pure red cell aplasia (n=8; 27%), myelodysplastic syndrome (n=3; 10%), aplastic anemia and agranulocytosis (n=1; 3% each). Bone marrow involvement was diagnosed concomitantly with SLE in 12 patients. Bone marrow biopsies showed fibrosis in 19 cases, including one case of pure red cell aplasia and one case of agranulocytosis and variable global marrow cellularity. Treatments included corticosteroids (90%), hydroxychloroquine (87%), rituximab (33%), intravenous immunoglobulins (30%), mycophenolate mofetil (20%) and ciclosporine (20%). After a median follow-up of 27 months (range: 1-142), 24 patients manifested complete improvement. No patient died. Conclusions: This registry comprises the largest series of SLE patients with bone marrow involvement. It demonstrates the strong link between SLE and bone marrow fibrosis. Patients with atypical or refractory cytopenia associated with SLE should undergo bone marrow examination to enable appropriate, and often effective, treatment. Long-term prognosis is good.
- Subjects
SYSTEMIC lupus erythematosus treatment; BONE marrow; MEDICAL history taking; HEMATOLOGY; ADRENOCORTICAL hormones; HORMONE therapy; CHLOROQUINE; ANATOMY; THERAPEUTICS
- Publication
QJM: An International Journal of Medicine, 2017, Vol 110, Issue 11, p701
- ISSN
1460-2725
- Publication type
Article
- DOI
10.1093/qjmed/hcx102